Lipella Pharma receives US FDA nod for expanded access programme for LP-310, an oral rinse formulation to treat oral lichen planus: Pittsburgh Saturday, February 8, 2025, 09:00 Hr ...

Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company focused on developing innovative therapies ...

Lipella Pharmaceuticals Inc. (LIPO), a clinical-stage biotechnology company, Wednesday said that the U.S. Food and Drug ...

PITTSBURGH - Lipella Pharmaceuticals Inc. (NASDAQ:LIPO), a biotech firm specializing in novel therapies for medical conditions lacking adequate treatments, has received FDA approval for an Expanded ...

Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on ...

Mayo Clinic researchers have identified a targeted therapy that could bring relief to people living with lichen planus, a ...

Teaser: Off-label systemic agents may treat inflammatory autoimmune vulvar diseases such as lichen sclerosus and lichen ...

Mayo Clinic researchers have identified a targeted therapy that could bring relief to people living with lichen planus, a ...

Consecutive patients suffering from symptomatic oral lichen planus who sought treatment at the university's dental hospital during 2000–02 were considered for inclusion in this study.